President Donald Trump is relying on drugmakers to lower U.S. prices on their own, but he might get less than he bargained for.

Bristol Myers Squibb (NYSE: BMY) today announced an expansion of its direct-to-patient offerings, providing eligible U.S. patients with steeply discounted prices for Eliquis ® (apixaban) and Sotyktu ® ...

Three Motley Fool contributors believe they've found dirt cheap value stocks to buy right now. Here's why they picked Merck ( MRK -1.30%), Novo Nordisk ( NVO -1.11%), and Pfizer ( PFE 0.04%).

A federal website notice, deleted and then reposted by the administration, provides a hint that more aggressive pricing policies may be coming.

Pharmacy benefit managers are working on a proposal to voluntarily change some business practices in an effort to avoid new regulation ...

Reuters Pfizer’s latest multibillion-dollar deal shows it isn’t backing down from the obesity fight. For investors, the stock offers a cheap ticket into the hottest corner of pharma. The company’s ...

In the pharmaceutical world, if you can't develop 'em, acquire 'em. That seems to be the philosophy behind Pfizer 's ( PFE -1.97%) latest big-ticket buy, specifically its purchase of clinical-stage ...

“Disconnected and fragmented” healthcare experiences -- such as prior authorization requirements and product accessibility issues -- are reducing the effectiveness of consumer ad spend, according to ...

A deal with Dutch startup VarmX gives CSL an option to buy a Phase 3-ready drug that could reverse the effects of popular anticoagulants like Eliquis, which carry the risk of internal bleeding.

Pfizer said it would buy a clinical stage biopharma company for up to $7 billion, as it eyes the lucrative weight-loss drug market currently dominated by Eli Lilly and Novo Nordisk.

The Trump administration is considering a regulatory approach to lower U.S. drug prices, potentially aligning them with those of other wealthy nations, sparking industry opposition and possible legal ...